ArticleFrontiers in molecular biosciences2021
Hub Long Noncoding RNAs with m6A Modification for Signatures and Prognostic Values in Kidney Renal Clear Cell Carcinoma.
Article in Frontiers in molecular biosciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 28 citations in OpenAlex.
- The lncRNA-m6A axis in cancer: a bidirectional regulatory network in tumor progression and therapeutic resistance.Journal of translational medicine · 2026Review
- m6A reader IGF2BP2-stabilized lncRNA LHX1-DT inhibits renal cell carcinoma (RCC) cell proliferation and invasion by sponging miR-590-5p.NPJ precision oncology · 2025Article
- Article
- AURKB promotes immunogenicity and immune infiltration in clear cell renal cell carcinoma.Discover oncology · 2024Article
- Machine Learning Gene Signature to Metastatic ccRCC Based on ceRNA Network.International journal of molecular sciences · 2024Article
- N6-methyladenosine methylation in kidney injury.Clinical epigenetics · 2023Review
- Insights into N6-methyladenosine (m6A) modification of noncoding RNA in tumor microenvironment.Aging · 2023Review
- Development and validation of cuproptosis-related lncRNA signatures for prognosis prediction in colorectal cancer.BMC medical genomics · 2023Article
- Construction and Validation of a Novel Prognosis Model in Colon Cancer Based on Cuproptosis-Related Long Non-Coding RNAs.Journal of clinical medicine · 2023Article
- The role of N6-methyladenosine (mFrontiers in medicine · 2023Review
- Crosstalk between N6-methyladenosine (m6A) modification and noncoding RNA in tumor microenvironment.International journal of biological sciences · 2023Review
- The Role of Long Noncoding RNA (lncRNAs) Biomarkers in Renal Cell Carcinoma.International journal of molecular sciences · 2022Review
- Identifying the role of transient receptor potential channels (TRPs) in kidney renal clear cell carcinoma and their potential therapeutic significances using genomic and transcriptome analyses.BMC medical genomics · 2022Article
- LncRNA LINC02257: A Potential Biomarker for Diagnosis and Prognosis of Colorectal Cancer.Journal of oncology · 2022Article
- Estradiol mediates the interaction of LINC01541 and miR-429 to promote angiogenesis of G1/G2 endometrioid adenocarcinomaFrontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.